Joyobrato Nath et al., 2020-10-01: Review of two decades of preclinical and clinical work on mebendazole, albendazole and flubendazole as anticancer agents, framed as drug repurposing and relabelling.
Substantial preclinical studies, as well as limited clinical trials, suggest noteworthy anticancer potency of these pleiotropic benzimidazoles, particularly as potent microtubule disrupting, anti-angiogenic, and anti-metastatic agents
Joyobrato Nath et al., 2020-10-01: Review of two decades of preclinical and clinical work on mebendazole, albendazole and flubendazole as anticancer agents, framed as drug repurposing and relabelling. Study type: narrative review. N: not applicable. Country: India (Cachar College, Assam). Dose: not applicable. Funder: not stated in the record. Declared conflicts: 'The authors have declared that no competing interests exist.' PARTLY because the authors themselves describe the clinical evidence as 'limited clinical trials', not established efficacy. Study type: review.
